Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in Vizsla Silver Corp., following a security incident at its Mexico project site on January 29, 2026, where ten individuals were taken and operations were temporarily suspended. The incident triggered a 14.87% stock price decline. The firm is also investigating similar claims against Telesat Corporation and Organogenesis Holdings Inc.

Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. following the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations for skin substitute grafts on December 26, 2025. The withdrawal exposes Organogenesis to increased competition from over 300 market participants. The company's stock price fell 10.14% to $5.28 per share on the news.

The global wound healing devices market is projected to grow from $29 billion in 2024 to $42 billion by 2032, driven by increasing chronic wounds, technological advancements, and an aging population.

DJS Law Group is investigating Organogenesis Holdings for potential securities law violations after the company's second phase 3 trial of ReNu failed to achieve its primary endpoint, causing a 12.39% stock price drop.

Organogenesis Holdings reported results from its second Phase 3 trial for ReNu, a knee osteoarthritis treatment, which did not achieve statistical significance for its primary endpoint, causing the stock to drop 15.49%.

Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.

Organogenesis reported mixed results for its ReNu knee osteoarthritis treatment in a second Phase 3 trial, showing numerical improvement in pain reduction but not meeting the primary statistical endpoint. The company plans to request a pre-BLA meeting with the FDA to discuss potential approval.

Organogenesis reported results from its second Phase 3 trial for ReNu, a knee osteoarthritis treatment, which did not meet the primary endpoint but showed numerical improvement in pain reduction. The company plans to request a pre-BLA meeting with the FDA to discuss submission pathway.

The global amniotic membrane market is expected to grow at a 7% CAGR by 2032, driven by increasing demand for advanced wound healing treatments and ophthalmological applications, with North America leading market expansion.

Organogenesis Holdings Inc. reported strong Q4 2024 revenue growth of 27%, driven by better-than-expected customer demand. However, the company expects a challenging operating environment in the first half of 2025 due to delays in the implementation of new Medicare coverage policies for skin substitute products. The company provided financial guidance for 2025 and updated on the progress of its ReNu clinical program.

CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the Truist Securities MedTech Conference, which is being held at the InterContinental Boston in Boston, MA on Tuesday, June 18th. Management will participate in 1x1 meetings. There will be no formal presentation.

ORGO earnings call for the period ending March 31, 2024.